Emily M. Leproust, an officer and director at Twist Bioscience Corp, has filed a notice to sell 4,573 shares of the company's common stock. This transaction is significant as it follows the recent vesting of restricted stock, which occurred on November 2, 2026. The sale, valued at approximately $619,191.97, is set to take place on November 3, 2026.

This filing is noteworthy as it reflects ongoing trends in the biotechnology sector, where executives often liquidate shares after stock vesting. Such actions can provide insights into the financial strategies of key personnel within the industry.

Background

Twist Bioscience Corp is a biotechnology company focused on the development of synthetic DNA and other biological products. The company is incorporated in Delaware and operates out of South San Francisco, California. It trades on the NASDAQ under the SEC file number 001-38720.

What the Filing Says

The SEC filing indicates that Leproust acquired the shares through a restricted stock vesting arrangement. The filing states, "Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution." This highlights the common practice among executives to sell shares to meet tax liabilities associated with stock compensation.

Impact

This transaction may affect shareholders and potential investors in Twist Bioscience as they analyze the motivations behind insider sales. The sale could also influence perceptions of the company's financial health and executive confidence.

What's Next

The filing does not say what happens next.